Qlucore targets the Japanese market
Qlucore targets the Japanese biotech and pharmaceutical markets through new partnership with Filgen Inc Agreement with Filgen will enable Qlucore to access this fast-growing market worth nearly £200bn Qlucore, a world leader in the development of bioinformatics software, has today announced an agreement with Filgen, Inc, one of Japan’s leading specialists in sales of science research equipment. Since its launch in 2004, Filgen has earned an international reputation for its work within the biotechnology and pharmaceutical sectors, including its highly regarded Biotechnology Analysis Service. Japan's biotech market is currently home to over 1,000 bio-based companies, accounting for revenues of more than 25 trillion yen (£190bn), according to ArgosBiotech, the biotechnology information directory for the life sciences community. As such, Japan is currently devoting substantial resources to developing universities and R&D facilities, encouraging biotech startups, and developing large communities of biotechnology companies and institutions in order to become one of the world's most advanced biotechnology regions.